Literature DB >> 10122540

Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

S Birch1, A Gafni.   

Abstract

Despite the growing literature on economic evaluation of health care programmes, little attention has been paid to the theoretical foundations of cost-effectiveness and cost utility analyses and the validity of the decision rules adopted as methods of achieving the stated goals. We show that although applications of the techniques can be used to pursue some managerial objectives in the context of highly constrained environments, such applications are inconsistent with both welfare economic objectives and the interpretations of the findings of these applications. Alternative strategies are identified as potential and practical methods for pursuing welfare economic objectives.

Mesh:

Year:  1992        PMID: 10122540     DOI: 10.1016/0167-6296(92)90004-k

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  54 in total

Review 1.  Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

Authors:  E McIntosh; C Donaldson; M Ryan
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

2.  Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.

Authors:  P Sendi; A J Palmer; A Gafni; M Battegay
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Estimating the "avoidable" burden of disease by Disability Adjusted Life Years (DALYs).

Authors:  S Hollinghurst; G Bevan; C Bowie
Journal:  Health Care Manag Sci       Date:  2000-01

Review 4.  Economics notes: types of economic evaluation.

Authors:  S Palmer; S Byford; J Raftery
Journal:  BMJ       Date:  1999-05-15

Review 5.  Willingness to pay as a measure of health benefits.

Authors:  M V Bala; J A Mauskopf; L L Wood
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.981

Review 6.  The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?

Authors:  C Donaldson
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

7.  Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

Authors:  Amiram Gafni; Stephen Birch
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

8.  Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.

Authors:  A Lytwyn; J W Sellors; J B Mahony; D Daya; W Chapman; N Ellis; P Roth; A T Lorincz; A Gafni
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

9.  Efficient use of health care resources: the interaction between improved health and reduced health related income loss.

Authors:  Michael Hoel
Journal:  Int J Health Care Finance Econ       Date:  2002-11

10.  Lean systems approaches to health technology assessment: a patient-focused alternative to cost-effectiveness analysis.

Authors:  John F P Bridges
Journal:  Pharmacoeconomics       Date:  2006-12       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.